IL13 and Alzheimer disease: IL‐4/IL‐13: Dupilumab, now licenced for AD treatment in the United States, Europe, China and Japan is a fully human anti‐IL‐4 receptor alpha monoclonal antibody, which inhibits IL‐4 and IL‐13.147